category,datetime,headline,id,image,related,source,summary,url
company,1768158000,Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome,138069486,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"BEDFORD, Mass., January 11, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodyâ€™s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced accelerated timelines for the completion of enrollment and a Phase 3 data readout from the EMPEROR",https://finnhub.io/api/news?id=b9a10151d05b8c1708eb83338ada35dd095fff3a6c4ba26bec63812e2fd3fc46
